ClinicalTrials.gg
CompletedNCT01820572Updated Jan 5, 2021Results posted

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

A Phase 3 interventional study of Belatacept and Tacrolimus in Kidney Transplantation, sponsored by Bristol-Myers Squibb. Completed at 117 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Men and women, ages 18-75 inclusive
  • Adult recipients of a renal allograft from a living donor or a deceased donor between 6-60 months prior to enrollment
  • Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) [Cyclosporine A (CsA) or Tacrolimus (TAC)] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (EC-MPS)/Mycophenolic acid (MPA), and
  • Stable renal function for 12 weeks prior to enrollment without new onset proteinuria
  • Calculated (cGFR) ≥30 and ≤75 mL/min/1.73 m2 [Modification of Diet in Renal Disease study (MDRD) 4-formula]

Exclusion criteria

Exclusion Criteria:

  • Recipients with Epstein-Barr virus (EBV) serostatus negative or unknown
  • History of acute rejection (AR) within 3 months prior to enrollment
  • History of antibody mediated rejection
  • Positive T-cell lymphocytotoxic cross match
  • Proteinuria >1 g/day or >0.5 g/day if diabetic
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
446 participants (actual)

Study arms

  • Experimental
    Belatacept

    Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months

    Drug: Belatacept

  • Active comparator
    CNI

    Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months

    Drug: Tacrolimus · Drug: Cyclosporine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Survive With a Functional Graft at 24 Months

    Percentage of participants who survive with a functional graft at 24 months post-randomization

    Time frame: at 24 Months

Secondary outcomes

  1. Percentage of Participants Who Survive With a Functional Graft at 12 Months

    Percentage of participants who survive with a functional graft at 12 months post-randomization

    Time frame: at 12 Months

  2. Number of Participants With a Biopsy Proven Acute Rejection (BPAR)

    The number of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization includes participants with at least one cellular and/or humoral BPAR event.

    Time frame: at 12 and 24 Months

  3. Number of Participants With Varying Severity of BPAR

    Number of participants in each severity of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization

    Time frame: at 12 and 24 months

  4. Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Percent Change

    Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Percent Change

    Time frame: at 12 and 24 months

  5. Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Adjusted Change

    Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Adjusted Change

    Time frame: at 12 and 24 months

  6. Mean Calculated Glomerular Filtration Rate (cGFR)

    Mean cGFR by study visit, as calculated by the 4-variable MDRD equation.

    Time frame: up to 24 months

  7. Slope Analysis of cGFR

    Slopes of cGFR as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization

    Time frame: at 12 and 24 Months

  8. Slope Analysis of 1/Serum Creatinine

    Slopes of 1/serum creatinine as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization

    Time frame: at 12 and 24 Months

  9. Percentage of Participants With > 5% and >10% Improvement Over Baseline cGFR

    Percentage of participants with \> 5% and \>10% improvement over baseline cGFR, at 12 and 24 months post-randomization

    Time frame: at 12 and 24 Months

  10. Mean Urine Protein/ Creatinine Ratio (UPCR)

    Urine protein/ creatinine ratio (UPCR) at baseline, 3, 6, 12 and 24 months post randomization

    Time frame: Up to 24 Months

  11. Mean Change From Baseline in Systolic and Diastolic Blood Pressure

    Mean change in systolic and diastolic blood pressure from baseline to 12 and 24 months post randomization

    Time frame: at 12 and 24 months

  12. Number of Antihypertensive Medications Used to Control Hypertension

    The total number of antihypertensive medications used to control hypertension

    Time frame: at baseline, 12 and 24 Months

  13. Number of Participants With Donor Specific Antibodies (DSA)

    Number of participants with donor specific antibodies (DSA) at Baseline/Day 1, and Months 12 and 24 post-randomization

    Time frame: at baseline, 12 and 24 months

  14. Mean Number of Symptom Occurrence and Symptom Distress

    The frequency of symptom occurrence and symptom distress as measured with the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59R (MTSOSD-59R) at baseline, Week 6, and Months 3, 6, and 12 post-randomization. Higher scores in the MTSOSD-59R indicate a greater symptom and symptom distress burden than lower scores.

    Time frame: up to 12 Months

  15. Number of Participants With an Adverse Event of Special Interest

    Number of participants with an adverse event of special interests. Adverse events of special interest include: Serious Infections, Post-Transplant Lymphoproliferative Disorder (PTLD), Progressive multifocal leukoencephalopathy (PML), Malignancies (other than PTLD) including non-melanoma skin carcinomas, Tuberculosis Infections, CNS infections, Viral Infections and Infusion related reactions.

    Time frame: 24 Months

  16. Number of Participants With Marked Laboratory Abnormalities

    Number of participants with Marked Laboratory Abnormalities

    Time frame: 24 Months

  17. Mean Change From Baseline in Vital Signs: Heart Rate

    The mean change from baseline in measured heart rate

    Time frame: at 12 and 24 months

07

Results

Posted Jan 5, 2021

Participant flow

Randomization
Participant flow — Randomization
MilestoneBelataceptCNI-Based Regimen
Started223223
Completed221222
Not completed21
Withdrew: Not treated21
Treatment Period
Participant flow — Treatment Period
MilestoneBelataceptCNI-Based Regimen
Started221222
Completed195186
Not completed2636
Withdrew: Adverse event127
Withdrew: Death33
Withdrew: Lack of efficacy10
Withdrew: Poor/non compliance03
Withdrew: Request to discontinue611
Withdrew: No longer meets study criteria310
Withdrew: Withdrew consent12

Outcome measures

PrimaryPercentage of Participants Who Survive With a Functional Graft at 24 Months

Percentage of participants who survive with a functional graft at 24 months post-randomization

Time frame:
at 24 Months
Reported as:
Number · Percentage
Percentage of Participants Who Survive With a Functional Graft at 24 Months
PercentageBelataceptCNI-Based Regimen
Percentage of Participants Who Survive With a Functional Graft at 24 Months98.2 (95.5 to 99.5)97.3 (95.2 to 99.4)
Statistical analysis
  • Belatacept vs CNI-Based Regimen · Difference in proportions: 0.9 · 95% CI -8.6 to 10.4
SecondaryPercentage of Participants Who Survive With a Functional Graft at 12 Months

Percentage of participants who survive with a functional graft at 12 months post-randomization

Time frame:
at 12 Months
Reported as:
Number · Percentage
Percentage of Participants Who Survive With a Functional Graft at 12 Months
PercentageBelataceptCNI-Based Regimen
Percentage of Participants Who Survive With a Functional Graft at 12 Months98.7 (96.1 to 99.7)99.1 (96.8 to 99.9)
Statistical analysis
  • Belatacept vs CNI-Based Regimen · Difference in proportions: -0.4 · 95% CI -9.9 to 9.0
SecondaryNumber of Participants With a Biopsy Proven Acute Rejection (BPAR)

The number of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization includes participants with at least one cellular and/or humoral BPAR event.

Time frame:
at 12 and 24 Months
Reported as:
Count of participants · Participants
Number of Participants With a Biopsy Proven Acute Rejection (BPAR)
ParticipantsBelataceptCNI-Based Regimen
at 12 Months184
at 24 Months189
SecondaryNumber of Participants With Varying Severity of BPAR

Number of participants in each severity of clinically suspected, biopsy proven acute rejection (AR) at 12 and 24 months post-randomization

Time frame:
at 12 and 24 months
Reported as:
Count of participants · Participants
Number of Participants With Varying Severity of BPAR
ParticipantsBelataceptCNI-Based Regimen
at 12 Months — Mild Acute (IA)22
at 12 Months — Mild Acute (IB)110
at 12 Months — Moderate Acute (IIA)70
at 12 Months — Moderate Acute (IIB)60
at 12 Months — Severe Acute (III)41
at 24 Months — Mild Acute (IA)24
at 24 Months — Mild Acute (IB)110
at 24 Months — Moderate Acute (IIA)71
at 24 Months — Moderate Acute (IIB)60
at 24 Months — Severe Acute (III)41
SecondaryMean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Percent Change

Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Percent Change

Time frame:
at 12 and 24 months
Reported as:
Mean · Percent Change
Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Percent Change
Percent ChangeBelataceptCNI-Based Regimen
at 12 Months13.2 (10.4 to 16.0)-0.3 (-2.9 to 2.4)
at 24 Months15.2 (11.9 to 18.6)0.3 (-2.9 to 3.4)
SecondaryMean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Adjusted Change

Mean change from baseline cGFR as calculated by the 4-variable MDRD equation to 12 and 24 months post-randomization - Adjusted Change

Time frame:
at 12 and 24 months
Reported as:
Mean · mL/min/1.73m²
Mean Change From Baseline of Calculated Glomerular Filtration Rate (cGFR) - Adjusted Change
mL/min/1.73m²BelataceptCNI-Based Regimen
at 12 Months5.6 (4.3 to 6.9)-0.7 (-2.0 to 0.6)
at 24 Months6.2 (4.7 to 7.7)-1.0 (-2.6 to 0.5)
SecondaryMean Calculated Glomerular Filtration Rate (cGFR)

Mean cGFR by study visit, as calculated by the 4-variable MDRD equation.

Time frame:
up to 24 months
Reported as:
Mean · mL/min/1.73m²
Mean Calculated Glomerular Filtration Rate (cGFR)
mL/min/1.73m²BelataceptCNI-Based Regimen
Screening49.8 (48.2 to 51.5)49.7 (48.2 to 51.2)
Baseline49.6 (48.0 to 51.2)50.7 (49.2 to 52.2)
Month 353.0 (51.1 to 54.9)50.2 (48.3 to 52.0)
Month 653.3 (51.3 to 55.3)50.9 (49.1 to 52.7)
Month 953.7 (51.8 to 55.6)50.7 (48.9 to 52.5)
Month 1255.5 (53.4 to 57.6)50.5 (48.7 to 52.4)
Month 1856.5 (54.5 to 58.5)51.3 (49.2 to 53.4)
Month 2455.7 (53.7 to 57.7)51.1 (49.0 to 53.2)
SecondarySlope Analysis of cGFR

Slopes of cGFR as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization

Time frame:
at 12 and 24 Months
Reported as:
Number · mL/min/1.73m²/month
Slope Analysis of cGFR
mL/min/1.73m²/monthBelataceptCNI-Based Regimen
Baseline to 12 Months0.241 (0.103 to 0.378)0.004 (-0.137 to 0.145)
Month 3 to Month 120.281 (0.072 to 0.490)-0.159 (-0.372 to 0.055)
Baseline to Month 240.685 (0.426 to 0.945)-0.112 (-0.379 to 0.155)
Month 3 to Month 240.658 (0.332 to 0.984)-0.277 (-0.614 to 0.060)
SecondarySlope Analysis of 1/Serum Creatinine

Slopes of 1/serum creatinine as plotted from baseline as well as from Month 3, to Month 12 and Month 24 post-randomization

Time frame:
at 12 and 24 Months
Reported as:
Number · mg/dL/month
Slope Analysis of 1/Serum Creatinine
mg/dL/monthBelataceptCNI-Based Regimen
Baseline to 12 Months0.034 (0.016 to 0.051)-0.003 (-0.020 to 0.015)
Month 3 to Month 120.033 (0.007 to 0.059)-0.021 (-0.048 to 0.006)
Baseline to Month 240.00868 (0.00537 to 0.01199)-0.00203 (-0.00544 to 0.00138)
Month 3 to Month 240.00814 (0.00412 to 0.01217)-0.00425 (-0.00842 to -0.00009)
SecondaryPercentage of Participants With > 5% and >10% Improvement Over Baseline cGFR

Percentage of participants with \> 5% and \>10% improvement over baseline cGFR, at 12 and 24 months post-randomization

Time frame:
at 12 and 24 Months
Reported as:
Number · Percentage
Percentage of Participants With > 5% and >10% Improvement Over Baseline cGFR
PercentageBelataceptCNI-Based Regimen
>5% improvement at 12 months53.428.7
>10% improvement at 12 months43.921.5
>5% improvement at 24 months54.329.6
>10% improvement at 24 months48.422.0
SecondaryMean Urine Protein/ Creatinine Ratio (UPCR)

Urine protein/ creatinine ratio (UPCR) at baseline, 3, 6, 12 and 24 months post randomization

Time frame:
Up to 24 Months
Reported as:
Mean · mg/mmol
Mean Urine Protein/ Creatinine Ratio (UPCR)
mg/mmolBelataceptCNI-Based Regimen
at Baseline17.80 (16.03 to 19.58)18.61 (15.08 to 22.14)
at 3 months22.87 (19.88 to 25.86)20.61 (15.50 to 25.73)
at 6 months23.42 (19.71 to 27.12)20.85 (15.36 to 26.35)
at 12 months29.11 (21.86 to 36.35)21.67 (17.70 to 25.65)
at 24 months28.81 (23.71 to 33.91)24.56 (19.01 to 30.10)
SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure

Mean change in systolic and diastolic blood pressure from baseline to 12 and 24 months post randomization

Time frame:
at 12 and 24 months
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure
mmHgBelataceptCNI-Based Regimen
Diastolic BP at 12 Months-1.5 (-2.9 to 0.0)-0.6 (-2.1 to 1.0)
Diastolic BP at 24 Months-1.7 (-3.3 to 0.0)0.5 (-1.3 to 2.3)
Systolic BP at 12 Months-1.6 (-4.0 to 0.9)0.1 (-2.5 to 2.8)
Systolic BP at 24 Months-1.3 (-4.1 to 1.6)1.2 (-1.7 to 4.1)
SecondaryNumber of Antihypertensive Medications Used to Control Hypertension

The total number of antihypertensive medications used to control hypertension

Time frame:
at baseline, 12 and 24 Months
Reported as:
Mean · Number of medications
Number of Antihypertensive Medications Used to Control Hypertension
Number of medicationsBelataceptCNI-Based Regimen
at Baseline2.1 (1 to 5)2.2 (1 to 6)
at 12 Months2.3 (1 to 7)2.2 (1 to 6)
at 24 Months2.3 (1 to 8)2.3 (1 to 7)
SecondaryNumber of Participants With Donor Specific Antibodies (DSA)

Number of participants with donor specific antibodies (DSA) at Baseline/Day 1, and Months 12 and 24 post-randomization

Time frame:
at baseline, 12 and 24 months
Reported as:
Count of participants · Participants
Number of Participants With Donor Specific Antibodies (DSA)
ParticipantsBelataceptCNI-Based Regimen
Pre Existing at baseline1026
De Novo at 12 Months29
De Novo at 24 Months214
SecondaryMean Number of Symptom Occurrence and Symptom Distress

The frequency of symptom occurrence and symptom distress as measured with the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59R (MTSOSD-59R) at baseline, Week 6, and Months 3, 6, and 12 post-randomization. Higher scores in the MTSOSD-59R indicate a greater symptom and symptom distress burden than lower scores.

Time frame:
up to 12 Months
Reported as:
Mean · Scores on a scale
Mean Number of Symptom Occurrence and Symptom Distress
Scores on a scaleBelataceptCNI-Based Regimen
Baseline symptom occurrence87.8 ± 20.0690.7 ± 21.04
Baseline symptom distress28.7 ± 27.0734.8 ± 28.30
week 6 symptom occurrence79.0 ± 16.5288.6 ± 21.36
week 6 symptom distress19.8 ± 21.4132.4 ± 29.55
Month 3 symptom occurrence80.5 ± 16.7489.9 ± 23.45
Month 3 symptom distress21.4 ± 23.0835.2 ± 32.04
month 6 symptom occurrence80.5 ± 17.5091.8 ± 23.72
month 6 symptom distress22.4 ± 22.1836.3 ± 31.39
month 12 symptom occurrence82.3 ± 20.0891.0 ± 22.33
month 12 symptom distress25.8 ± 25.3234.4 ± 30.82
SecondaryNumber of Participants With an Adverse Event of Special Interest

Number of participants with an adverse event of special interests. Adverse events of special interest include: Serious Infections, Post-Transplant Lymphoproliferative Disorder (PTLD), Progressive multifocal leukoencephalopathy (PML), Malignancies (other than PTLD) including non-melanoma skin carcinomas, Tuberculosis Infections, CNS infections, Viral Infections and Infusion related reactions.

Time frame:
24 Months
Reported as:
Number · participants
Number of Participants With an Adverse Event of Special Interest
participantsBelataceptCNI-Based Regimen
Serious Infections3744
PTLD10
PML00
Malignancies1712
Tuberculosis infections00
CNS Infections00
Viral Infections59
Infusion Related Reactions130
SecondaryNumber of Participants With Marked Laboratory Abnormalities

Number of participants with Marked Laboratory Abnormalities

Time frame:
24 Months
Reported as:
Number · Participants
Number of Participants With Marked Laboratory Abnormalities
ParticipantsBelataceptCNI-Based Regimen
Hemoglobin (Abnormal Low)00
Hemoglobin (Abnormal high)00
Platelet count (Abnormal low)01
Leukocytes (Abnormal low)00
Lymphocytes (Abnormal low)2910
Lymphocytes (Abnormal high)00
Neutrophils Absolute (Abnormal low)53
Alanine Aminotransferase (Abnormal High)00
Alkaline Phosphatase (Abnormal High)00
Aspartate Aminotransferase (Abnormal High)01
Total Bilirubin (Abnormal High)00
Creatine (Abnormal High)54
Protein/Creatinine Ratio (Abnormal High)00
Bicarbonate (Abnormal High)01
Total Calcium (Abnormal low)03
Total Calcium (Abnormal high)12
Magnesium (Abnormal low)00
Magnesium (Abnormal high)00
Phosphorus (Abnormal Low)1412
Potassium (Abnormal low)32
Potassium (Abnormal high)15
Sodium (Abnormal low)49
Sodium (Abnormal high)01
Albumin (Abnormal low)00
Total Cholesterol (Abnormal High)1317
Serum Glucose (Abnormal low)00
Serum Glucose (Abnormal high)1818
Triglycerides (Abnormal high)22
Uric Acid (Abnormal high)1530
SecondaryMean Change From Baseline in Vital Signs: Heart Rate

The mean change from baseline in measured heart rate

Time frame:
at 12 and 24 months
Reported as:
Mean · beats per minute (bpm)
Mean Change From Baseline in Vital Signs: Heart Rate
beats per minute (bpm)BelataceptCNI-Based Regimen
Change from baseline at 12 months-1.8 (-3.3 to -0.2)-0.6 (-2.2 to 1.0)
Change from baseline at 24 months-1.9 (-3.5 to -0.3)1.0 (-0.8 to 2.8)

Adverse events

Collected over 116 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belatacept4/221 (1.8%)107/221 (48.4%)174/221 (78.7%)
CNI-Based Regimen5/222 (2.3%)95/222 (42.8%)168/222 (75.7%)
Most frequent serious events
Showing 10 of 208
Most frequent serious events
EventBelataceptCNI-Based Regimen
Kidney transplant rejectionImmune system disorders19/2217/222
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/2215/222
Urinary tract infectionInfections and infestations7/2217/222
PneumoniaInfections and infestations5/2217/222
UrosepsisInfections and infestations6/2213/222
DiarrhoeaGastrointestinal disorders1/2216/222
GastroenteritisInfections and infestations1/2216/222
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/2215/222
Acute kidney injuryRenal and urinary disorders4/2215/222
SepsisInfections and infestations4/2212/222
Most frequent other events
Showing 10 of 23
Most frequent other events
EventBelataceptCNI-Based Regimen
DiarrhoeaGastrointestinal disorders47/22161/222
NasopharyngitisInfections and infestations44/22150/222
Urinary tract infectionInfections and infestations37/22133/222
Oedema peripheralGeneral disorders22/22135/222
CoughRespiratory, thoracic and mediastinal disorders31/22120/222
HypertensionVascular disorders29/22121/222
HeadacheNervous system disorders27/22123/222
BronchitisInfections and infestations23/22118/222
ArthralgiaMusculoskeletal and connective tissue disorders21/22123/222
FatigueGeneral disorders22/22115/222

Baseline characteristics

Age, Continuous
Age, Continuous(Years)BelataceptCNI-Based RegimenTotal
Median55.0 ± 11.354.0 ± 11.754.0 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)BelataceptCNI-Based RegimenTotal
Female7372145
Male150151301
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BelataceptCNI-Based RegimenTotal
Hispanic or Latino91524
Not Hispanic or Latino8279161
Unknown or Not Reported132129261
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BelataceptCNI-Based RegimenTotal
American Indian or Alaska Native000
Asian134
Native Hawaiian or Other Pacific Islander000
Black or African American242448
White191187378
More than one race000
Unknown or Not Reported7916
08

Study locations

117 sites
  • UAB Division of Nephrology
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85027, United States
  • Loma Linda University Medical Center (LLUMC) - Children's Hospital - Transplantation Institute
    Loma Linda, California 92354, United States
  • UCLA Kidney Transplant Research Office
    Los Angeles, California 90024, United States
  • Keck Medical Center of USC (PI Address)
    Los Angeles, California 90033, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Transplant Research Institute (PI Address)
    Los Angeles, California 90057, United States
  • University of California, San Francisco (UCSF)-Kidney Transplant Service
    Sacramento, California 95817, United States
  • California Institute Of Renal Research
    San Diego, California 92123, United States
  • California Pacific Medical Center, Depart of Transplantation (PI Address)
    San Francisco, California 94115, United States
  • UCSF Medical Center
    San Francisco, California 94143-0116, United States
  • University of Colorado Denver (PI Address)
    Aurora, Colorado 80045, United States
  • Denver Nephrologists, PC
    Denver, Colorado 80218, United States
  • Yale Medical Group
    New Haven, Connecticut 06520, United States
  • Florida Hospital Transplant Institute (PI Address)
    Orlando, Florida 32804, United States
  • Central Pharmacy
    Saint Petersburg, Florida 33716, United States
  • Tampa General Medicine Group
    Tampa, Florida 33606, United States
  • Emory University
    Atlanta, Georgia, United States
  • Medical College of Georgia at Augusta University
    Augusta, Georgia 30912, United States
  • RUSH University Transplant Program (PI Address)
    Chicago, Illinois 60612, United States
  • University of Wisconsin School of Medicine and Public Health (PI Address)
    Chicago, Illinois, United States
  • University of Iowa Health Care (PI Address)
    Iowa City, Iowa 52242-1101, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Maine Transplant Program
    Portland, Maine 04102, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford's Transplant Institute
    Detroit, Michigan 48202, United States
  • St. Clair Nephrology Research
    Roseville, Michigan 48066, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington Univ School of Med
    Saint Louis, Missouri 63110, United States
  • University or Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Saint Barnabas Medical Center
    Livingston, New Jersey 07006, United States
  • University of Buffalo
    Buffalo, New York 14215, United States
  • Recanati/Miller Transplantation Institue (PI Address)
    New York, New York 10029, United States
  • Carolinas Medical Center (PI Address)
    Charlotte, North Carolina 28203, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • East Carolina Univ Nephrology Clin Res. Lab
    Greenville, North Carolina 27834, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106-5055, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Central PA Transplant Foundation
    Harrisburg, Pennsylvania 17104, United States
  • Drexel University College of Medicine
    Philadelphia, Pennsylvania 19102, United States
  • Penn Medicine
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213-2582, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina, SCTR Research Nexus
    Charleston, South Carolina 29425, United States
  • Methodist University Hospital Transplant Institute (PI Address)
    Memphis, Tennessee 38104, United States
  • Vanderbilt University Medical Center- GI Research Office
    Nashville, Tennessee 37212-1375, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor All Saints Medical Center at Ft. Worth
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Memorial Hermann - Texas Medical Center (Tmc), The University Of Texas Medical School At Houston
    Houston, Texas 77030, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah Depart of Nephrology (PI Address)
    Salt Lake City, Utah 84132, United States
  • University of Virginia Health System (PI Address)
    Charlottesville, Virginia 22903, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298-0160, United States
  • Swedish Medical Center-Swedish Organ Transplant and Liver Center
    Seattle, Washington 98104, United States
  • University of Washington Medical Center (PI Address & Study Supplies Address)
    Seattle, Washington 98195, United States
  • Providence Sacred Heart Medical Center and Childrens Hospital
    Spokane, Washington 99204, United States
  • Medical College of WI Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Local Institution
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1093, Argentina
  • Local Institution
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1425, Argentina
  • Local Institution
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1118AAT, Argentina
  • Local Institution
    Mendoza, Buenos Aires M5501ACJ, Argentina
  • Local Institution
    Cardoba, Cordoba 5016, Argentina
  • Local Institution
    Rosario, Santa FE Santa Fe, 2000, Argentina
  • Local Institution
    Buenos Aires, 1155, Argentina
  • Local Institution
    Caba, 1425, Argentina
  • Local Institution
    Cordoba, X5016KEH, Argentina
  • Local Institution
    Santa Fe, 3000, Argentina
  • Local Institution
    Feldkirch, 6800, Austria
  • Local Institution
    Graz, 8036, Austria
  • Local Institution
    Innsbruck, 6020, Austria
  • Local Institution
    Linz, 4020, Austria
  • Local Institution
    Wien, 1090, Austria
  • Local Institution
    Cali, Valle DEL Cauca, Colombia
  • Local Institution
    Bogota, Colombia
  • Local Institution
    Paris, Cedex 15, France
  • Local Institution
    Bois-Guillaume, 76230, France
  • Local Institution
    Bordeaux, 33076, France
  • Local Institution
    Brest Cedex 2, 29609, France
  • Local Institution
    Creteil, 94010, France
  • Local Institution
    GRENOBLE Cedex 09, France
  • Local Institution
    Le Kremilin Bicretre, 942875, France
  • Local Institution
    Lyon Cedex 03, 69437, France
  • Local Institution
    Paris Cedex 10, 75475, France
  • Local Institution
    Strasbourg Cedex, 67091, France
  • CHU Rangueil
    Toulouse Cedex 8, 31059, France
  • Local Institution
    Berlin, 10117, Germany
  • Local Institution
    Dresden, 01307, Germany
  • Local Institution
    Erlangen, 91054, Germany
  • Local Institution
    Essen, 45147, Germany
  • Local Institution
    Frankfurt am Main, Germany
  • Local Institution
    Hamburg, 20246, Germany
  • Local Institution
    Hannover, 30625, Germany
  • Local Institution
    Heidelberg, 69120, Germany
  • Local Institution
    Kiel, 24105, Germany
  • Local Institution
    Lubeck, 23538, Germany
  • Local Institution
    Mannheim, 68167, Germany
  • Local Institution
    Muenchen, 81675, Germany

Showing the first 100 of 117 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2013 to primary completion in Oct 2019, 78 months.

Results were first posted in Jan 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2013
First posted
Mar 29, 2013
StartActual
Mar 27, 2013
Primary completionActual
Oct 24, 2019
CompletionActual
Oct 24, 2019
Results first posted
Jan 5, 2021
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01820572
Responsible party
Sponsor
First posted
Mar 29, 2013
Start date
Mar 27, 2013
Primary completion
Oct 24, 2019
Completion
Oct 24, 2019
Results posted
Jan 5, 2021
Last update
Jan 5, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion